Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21419245 | 0.89 | HRH1 (0.43) | HRH1NOS2SLC6A3 | |
| SCHEMBL11926965 | 0.80 | HRH1 (0.45) | HRH1 | |
| SCHEMBL7079640 | 0.79 | HRH1 (0.42) | HRH1 | |
| SCHEMBL6676408 | 0.79 | HRH1 (0.42) | HRH1 | |
| SCHEMBL28730380 | 0.76 | KCNH2 (0.41) | KCNH2NOS2SLC6A3DRD2HTR6 | |
| SCHEMBL18999242 | 0.75 | MIF (0.40) | HRH1 | |
| SCHEMBL3760695 | 0.75 | HRH1 (0.44) | HRH1 | |
| SCHEMBL12926881 | 0.75 | HRH1 (0.44) | HRH1 | |
| SCHEMBL21699960 | 0.75 | SLC6A3 (0.52) | HRH1KCNH2NOS2SLC6A3DRD2 | |
| SCHEMBL30945393 | 0.75 | KCNH2 (0.39) | KCNH2NOS2SLC6A3DRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196423-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-9982016-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-9982016-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160194357-A1 | Novel NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9187525-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9169293-B2 | NPR-B agonists | Shire Orphan Thereapies GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-8551938-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8546523-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | HRH1 322/4885KCNH2 1714/4885NOS2 594/4885 |
| US-10196423-B2 | NPR-B agonists | NPR1, NPR3, NPBWR1 | HRH1 314/4885KCNH2 1879/4885NOS2 538/4885 |
| US-20170313743-A1 | NPR-B Agonists | NPR1, NPR3, NPBWR1 | HRH1 314/4885KCNH2 1879/4885NOS2 538/4885 |
| US-20160194357-A1 | Novel NPR-B Agonists | NPR1, NPR3, NPBWR1 | HRH1 322/4885KCNH2 1714/4885NOS2 594/4885 |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | HRH1 322/4885KCNH2 1714/4885NOS2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.